8059 —Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

Introduction: Endocrine therapies (ETs) are associated with alopecia (EIA) in 15-25% of patients. There are no approved therapies for EIA. The purpose of this review is to provide dermatologists and oncologists with a foundation for the practical understanding of 5 α-reductase inhibitors and spironolactone for breast cancer patients and survivors with alopecia attributed to ETs, including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research